(Q61921265)
Statements
REFORMS (English)
0 references
A Randomized, Multicenter, Two Arm, Open Label, Twelve Week Phase IIIb Study to Evaluate the Tolerability of Rebif (New Formulation) (IFN Beta-1a) and Betaseron (IFN Beta-1b) in IFN-naive Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) Followed by a Single Arm, Eighty-two Week Minimum, Rebif (New Formulation) Only Safety Extension (English)
0 references
December 2006
0 references
November 2007
0 references
129
0 references
18 year
0 references
60 year
0 references